Form 4: Ionis Pharmaceuticals Director Equity Grants Detailed

Joan E. Herman, a Director at Ionis Pharmaceuticals, reports the grant of stock options and restricted stock units with specific vesting conditions and a cap on annual equity compensation.

Summary

• Joan E. Herman, a Director at Ionis Pharmaceuticals (IONS), has reported the grant of equity awards.
• These grants include non-qualified stock options and restricted stock units (RSUs).
• The stock options have an exercise price of $79.19 and were granted on July 1, 2026.
• The RSUs represent a contingent right to receive one share of Ionis common stock or its cash equivalent.
• Both the stock options and RSUs vest 100% on the first anniversary of the grant date or the next annual stockholder meeting, whichever is earlier.
• The total annual equity compensation for non-employee directors in 2026 is capped at $400,000 based on grant date fair value.
• As of July 1, 2026, none of the granted options or RSUs were vested or exercisable.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine equity grants to a director rather than significant financial performance or strategic shifts.

Positives

• Director compensation includes equity awards, aligning director interests with shareholders.
• A clear policy is in place to cap annual equity compensation for non-employee directors at $400,000.
• Vesting schedules are designed to encourage long-term commitment, with full vesting occurring on the first anniversary or next annual meeting.

Negatives

• The grants are not immediately exercisable or vested as of the reporting date (July 1, 2026).

Risks

• The value of the stock options is subject to market fluctuations and the company's stock performance.
• The vesting of RSUs and options is contingent on continued service as a director.

Future Outlook

The filing details future vesting and exercisability of equity awards granted on July 1, 2026, with options expiring on June 30, 2036, and RSUs to be delivered following vesting.

Management Comments

• Grants were adjusted downward to ensure non-employee director's annual equity compensation in 2026 does not exceed $400,000 based on aggregate grant date fair value.
• Stock options and Restricted Stock Units vest 100% on either the first anniversary of the grant date or the next regularly scheduled annual meeting of stockholders, whichever occurs earlier.

Industry Context

StockSavvy.ai notes that the reporting of equity grants to directors is standard practice for publicly traded companies, particularly in the biopharmaceutical sector where long-term incentives are crucial for attracting and retaining experienced leadership.

Stakeholder Impact

• Shareholders: The equity grants align director compensation with shareholder interests, potentially driving long-term value creation.
• Employees: While not directly impacting employees, the compensation structure for directors reflects the company's overall approach to incentivizing leadership.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Vesting of stock options and restricted stock units on or after July 1, 2027.
• Delivery of common stock or cash equivalent for vested RSUs on July 15th following vesting.
• Expiration of stock options on June 30, 2036.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Form 4, SEC Filing, Director Compensation, Equity Awards, Stock Options, Restricted Stock Units, Joan E. Herman, Vesting Schedule, Beneficial Ownership